Penumbra Inc. (PEN)
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Reasons Growth Investors Will Love Penumbra (PEN)
Penumbra (PEN) possesses solid growth attributes, which could help it handily outperform the market.
Here is Why Growth Investors Should Buy Penumbra (PEN) Now
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Penumbra (PEN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Richard Newitter - Truist Securities Robert Marcus - JPMorgan Joanne Wuensch - Citi Michael Sarcone - Jefferies Samantha Kurtz - Piper Sandler Michael Kratky - Leerink Pito Chickering - Deutsche Bank Michael Matson - Needham Operator Good afternoon. My name is Jeremy, and I will be your conference operator today.
Penumbra (PEN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Penumbra (PEN) Q3 Earnings and Revenues Top Estimates
Penumbra (PEN) came out with quarterly earnings of $0.85 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.67 per share a year ago.
Penumbra (PEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Penumbra (PEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Penumbra Stock Zoomed 4% Higher Today
The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares.
Here's Why You Should Retain Penumbra Stock in Your Portfolio Now
Investors feel optimistic about PEN's strong growth prospects in the Thrombectomy business. Yet, unfavorable forex impacts are concerning.
Why Penumbra Stock Zoomed Nearly 5% Higher Today
A researcher initiated coverage of the medical device maker with a confident buy recommendation. He sees multiple positive factors that should propel its growth.
